Production and Release Testing of Ovine Atadenovirus Vectors
Gene-directed enzyme prodrug therapy (GDEPT) is an emerging approach for the treatment of cancers. A variety of viral vectors have been used to deliver genes that encode the relevant enzymes, and some have been tested in clinical trials. To ensure the potency and efficacy of such vectors and to obtain regulatory approval to administer them to humans, it is necessary to develop a suite of assays that provide quality assurance. New GDEPT vectors based on ovine atadenovirus and Escherichia coli purine nucleoside phosphorylase (PNP) have been developed for first time use in humans in a phase I trial for the treatment of prostate cancer. Here we describe methods for their production together with several quality-control assays. In particular, a functional cell killing assay was devised to measure the potency of PNP-GDEPT vectors, the principles of which could easily be adapted to other systems.
Key WordsOvine atadenovirus vectors PNP-GDEPT prostate cancer
- 1.Curiel, D. and Douglas, J., eds. (2002) Adenoviral Vectors for Gene Therapy. Academic Press, San Diego, CA.Google Scholar
- 7.Martiniello-Wilks, R., Wang, X.-Y., Voeks, D., et al. (2004) Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J. Gene Med. 6, 1343–1357.PubMedCrossRefGoogle Scholar
- 11.Löser, P., Kümin, D., Hillgenberg, M., Both, G., and Hofmann, C. (2001) Preparation of ovine adenovirus vectors. In Methods in Molecular Medicine, Gene Therapy Protocols, 2nd ed. (Morgan, J., ed.), Humana Press, Totowa, NJ, Vol. 69, pp. 415–426.Google Scholar
- 17.Spearman, C. (1908) The method of right and wrong cases (constant stimuli) without Gauss formulae. Br. J. Psychol. 2, 227–242.Google Scholar